# A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors

> **NCT05267899** · PHASE1 · UNKNOWN · sponsor: **Zhejiang Haichang Biotech Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** WGI-0301

## Key facts

- **NCT ID:** NCT05267899
- **Lead sponsor:** Zhejiang Haichang Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-01
- **Primary completion:** 2024-10-15
- **Final completion:** 2024-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05267899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05267899, "A Phase I First in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of WGI-0301 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05267899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*